Congratulations to BioNJ Member Novartis Pharmaceuticals for receiving two new FDA approvals for Cosentyx to treat patients with Ankylosing Spondylitis and Psoriatic Arthritis. This is in addition to the approval of Novartis’ ofatumumab (Arzerra Injection) for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive chronic lymphocytic leukemia.
The innovation never ends… BioNJ Member Eli Lilly and Incyte announced the submission of a new drug application to the FDA for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis.
BioNJ Member ThromboGenics announced that the first patient has been enrolled in its Phase II CIRCLE study evaluating the efficacy and safety of multiple doses of ocriplasmin in inducing total posterior vitreous detachment in patients with non-proliferative diabetic retinopathy.
BioNJ Member Sanofi and Regeneron announced that the FDA has accepted for review the Biologics License Application for sarilumab, an investigational, human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of patients with active, moderate-to-severe rheumatoid arthritis.
BioNJ applauds the Obama administration for their Cancer ‘Moonshot’ initiative led by Vice President Joe Biden. With the ever-increasing list of cancer therapies, New Jersey’s life sciences community continues to be a driving force in the discovery and development of new life-changing therapies and medicines for cancer patients.
Come celebrate New Jersey’s innovation at BioNJ’s 23rd Annual Gateway Gala, Dinner Meeting & Innovation Celebration on February 4, 2016. The inspirational evening will include a Keynote by the Honorable Patrick Kennedy, the presentation of the Dr. Sol J. Barer Award to Clive Meanwell, M.D., Ph.D., Founder and CEO of The Medicines Company and the Innovator Awards to be presented by two very special guests. More on that next week! Register now.
Click here to read this week’s Weekender.